Welcome!
iX Biopharma
Broker's Calls
iX Biopharma 'warming up' with new outlicensing agreement with Seelos Therapeutics: PhillipCapital
PhillipCapital analyst Paul Chew maintains “buy” rating on iX Biopharma with an increased target price to 35.5 cents
December 01, 2021
Healthcare
iX Biopharma inks exclusive agreement with Seelos worth up US$239 mil
iX Biopharma will also receive double digit percentage royalties on future net sales of any licensed product.
November 24, 2021
Deals, joint ventures & alliances
iX Biopharma signs agreement with China Resources Pharmaceutical Commercial Group to distribute Wafesil in China
The licensing agreement runs for an initial term of 10 years.
September 30, 2021
Results
iX Biopharma narrows FY2021 loss on higher sales
The demand in China grew thanks to careful spent on marketing which helped drive awareness and interest.
August 23, 2021
Company in the news
iX Biopharma to export medicinal cannabis wafers in New Zealand
The agreement will allow iX Biopharma to access New Zealand’s pharmaceutical market.
July 27, 2021
Healthcare
iX Biopharma exploring spin-off and listing of pharmaceutical business on HKEX
iX Biopharma intends to spin-off its pharmaceutical business by way of a listing on the main board of the HKEX.
July 12, 2021
Company in the news
iX Biopharma gets green light to export medicinal cannabis wafers
iX Biopharma says it will commence supply of the wafers to Brazil as part of its overseas market expansion.
June 28, 2021
Broker's Calls
Broker's Digest: Venture Corp, Grand Venture Technology, Sasseur REIT, iX Biopharma, SGX
See the analysts' recommendations and target prices here.
June 18, 2021
Healthcare
iX Biopharma ketamine wafers to be evaluated for cancer pain treatment in Australian study
The company says the study unlocks Wafermine’s potential to address the global cancer pain market, estimated at US$5.5 bil.
June 15, 2021
Broker's Calls
Continue to 'buy' iX Biopharma as expanded product use and capacity should provide stock catalysts: PhillipCapital
PhillipCapital has maintained its target price of 44.5 cents for iX Biopharma.
June 14, 2021